公开(公告)号：US20240000801A1

公开(公告)日：2024-01-04

申请号：US17824478

申请日：2022-05-25

Applicant: Axar Laboratories, Inc.

Inventor： William Hite ,  Nilesh Parikh ,  Kapil Swain ,  Jonathan Moreno

IPC: A61K31/573 ,  A61K31/58 ,  A61K31/56 ,  A61K47/36 ,  A61K47/02 ,  A61K47/18 ,  A61K47/10 ,  A61K47/44 ,  A61K9/00 ,  A61K9/10

CPC classification number: A61K31/573 ,  A61K31/58 ,  A61K31/56 ,  A61K47/36 ,  A61K47/02 ,  A61K9/10 ,  A61K47/10 ,  A61K47/44 ,  A61K47/186 ,  A61K9/0014 ,  A61K47/183

Abstract: The disclosure provides pharmaceutical topical otic, ophthalmic, or nasal aqueous suspension formulations that comprise a corticosteroid; a chelating agent; a xanthan gum; an ionic tonicity agent; a pH from 5 to 6; and balance water. Such formulations comprise amounts of each of the xanthan gum and the ionic tonicity agent that together result in the formulation having: (i) a viscosity of from 4000 centipoises (“cps”) to 8000 centipoises (“cps”), and (ii) an osmolality of from 250 milliosmoles (“mOsm”) to 350 mOsm, and (iii) are readily redispersible.

公开(公告)号：US11857556B2

公开(公告)日：2024-01-02

申请号：US17239685

申请日：2021-04-26

Applicant: Rajendar Medishetty ,  Agadihiremath Thippeswamy ,  Sreenivasa Reddy ,  Shivakumar Pradeep

Inventor： Rajendar Medishetty ,  Agadihiremath Thippeswamy ,  Sreenivasa Reddy ,  Shivakumar Pradeep

IPC: A61K31/58 ,  A61K9/00 ,  A61P17/14 ,  A61K47/10 ,  A61K47/14 ,  A61K47/44

CPC classification number: A61K31/58 ,  A61K9/0014 ,  A61K47/10 ,  A61K47/14 ,  A61K47/44 ,  A61P17/14

Abstract: The present invention relates to a composition for topical application for preventing hair loss, androgenic alopecia (AA) and stimulating hair growth having dutasteride. The composition for topical application for preventing hair loss and stimulating hair growth according to the present invention provides equal or superior hair loss prevention and hair growth stimulating effects while using much smaller dosage than the conventional compositions (oral dosage form) which use finasteride and dutasteride.

公开(公告)号：US11839632B2

公开(公告)日：2023-12-12

申请号：US18178847

申请日：2023-03-28

Applicant: Seed Health, Inc.

Inventor： Tye Jensen ,  Joseph E. Kovarik

IPC: A61K35/74 ,  A61K31/715 ,  A61K31/58 ,  A61K38/17 ,  A61K35/00

CPC classification number: A61K35/74 ,  A61K31/58 ,  A61K31/715 ,  A61K38/1709 ,  A61K38/1758 ,  A61K2035/11

Abstract: Compositions, systems and methods of improving the health of the microbiome of an individual's skin relate to the provision of skin contacting formulations containing beneficial bacteria and other microbe components to foster the growth and maintenance of a healthy skin microbiome. Embodiments include methods for treating an individual suffering from acne vulgaris by topically administering a composition that includes live bacteria selected from the group consisting of L. reuteri, L. johnsonii, L. crispatus, C. acnes, and Nitrosomonas eutropha, that have been modified by using a using a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Francisella 1(Cpf1) system to reduce the production of a virulence factor of the bacteria.

公开(公告)号：US11826388B2

公开(公告)日：2023-11-28

申请号：US18087545

申请日：2022-12-22

Applicant: SEED HEALTH, INC.

Inventor： Sheri Simmons ,  Shanthi Parkar ,  Erin A. Miller ,  Joseph E. Kovarik

IPC: A61K35/74 ,  A61K31/715 ,  A61K31/58 ,  A61K38/17 ,  A61K35/00

CPC classification number: A61K35/74 ,  A61K31/58 ,  A61K31/715 ,  A61K38/1709 ,  A61K38/1758 ,  A61K2035/11

Abstract: Compositions, systems and methods of improving the health of the microbiome of an individual's skin relate to the provision of skin contacting formulations containing beneficial bacteria and other microbe components to foster the growth and maintenance of a healthy skin microbiome. A topical application of Lactobacillus crispatus is employed to ameliorate skin barrier damage and inflammation using unique combinations of probiotics, prebiotics, and other skin-beneficial ingredients, effectively treating inflammatory skin diseases, such as atopic dermatitis, psoriasis and acne. The topical application of Lactobacillus crispatus to an individual's skin reduces inflammation through the production of tryptophan metabolites that act as AHR agonists.

公开(公告)号：US20230372365A1

公开(公告)日：2023-11-23

申请号：US18027758

申请日：2021-09-30

Applicant: Andrew D. LEVIN ,  Danielle FELDMAN ,  Eliem Therapeutics (UK) Ltd

Inventor： Andrew D. Levin ,  Danielle Feldman

IPC: A61K31/58 ,  A61K45/06

CPC classification number: A61K31/58 ,  A61K45/06

Abstract: The invention relates to methods of treating fibromyalgia in a human subject by providing the steroid of Formula (I):

公开(公告)号：US11819816B2

公开(公告)日：2023-11-21

申请号：US16806961

申请日：2020-03-02

Applicant: INVENTAGE LAB, INC.

Inventor： Ju Hee Kim

IPC: B01J13/06 ,  A61K9/00 ,  B01L3/00 ,  B01J19/00 ,  A61K9/16 ,  B01F33/302 ,  B01F33/30 ,  B01F33/3011 ,  A61K9/14 ,  A61K31/365 ,  A61K31/58 ,  C08J5/00 ,  B01J2/06 ,  B01J2/02

CPC classification number: B01J13/06 ,  A61K9/0019 ,  A61K9/146 ,  A61K9/1647 ,  A61K9/1682 ,  A61K31/365 ,  A61K31/58 ,  B01F33/30 ,  B01F33/302 ,  B01F33/3011 ,  B01J19/0093 ,  B01L3/502707 ,  C08J5/00 ,  B01J2/02 ,  B01J2/06 ,  B01J2219/00889 ,  B01L2200/0647 ,  B01L2300/0816 ,  B01L2300/161 ,  C08J2367/04

Abstract: Provided is an apparatus for a mass production of microspheres and a multichannel forming device incorporatable therein. The apparatus includes a multi-channel microsphere forming unit, a first source material reservoir containing the first source material and in fluid communication with the plurality of first microchannels, a second source material reservoir containing the second source material and in fluid communication with the plurality of second microchannels, a flow control unit configured to supply a first gas to the first source material reservoir at a first source material flow rate and to supply a second gas to a second source material reservoir at a second source material flow rate and a product reservoir for accommodating the microspheres formed from the multi-channel forming unit.

公开(公告)号：US11819498B2

公开(公告)日：2023-11-21

申请号：US17136608

申请日：2020-12-29

Applicant: UNM RAINFOREST INNOVATIONS

Inventor： Vojo P. Deretic ,  Jia Cassano ,  Bhawana Bissa

IPC: A61K31/4164 ,  A61K31/4184 ,  A61K31/438 ,  A61K31/133 ,  A61K31/198 ,  A61K31/155 ,  A61K31/4439 ,  A61K31/585 ,  A61K31/7004 ,  A61K31/618 ,  A61K31/4365 ,  A61K31/496 ,  A61K31/519 ,  A61K31/437 ,  A61K31/485 ,  A61K31/4545 ,  A61K31/4418 ,  A61K31/192 ,  A61K31/58 ,  A61K31/365

CPC classification number: A61K31/4439 ,  A61K31/133 ,  A61K31/155 ,  A61K31/192 ,  A61K31/198 ,  A61K31/365 ,  A61K31/4164 ,  A61K31/4184 ,  A61K31/437 ,  A61K31/438 ,  A61K31/4365 ,  A61K31/4418 ,  A61K31/4545 ,  A61K31/485 ,  A61K31/496 ,  A61K31/519 ,  A61K31/58 ,  A61K31/585 ,  A61K31/618 ,  A61K31/7004

Abstract: The present invention is directed to the discovery that AMPK activation through Galectin 9 induces autophagy and affects other related processes in response to lyosomal damage which occurs and the use of that mechanism in the treatment of autophagy disease states and/or conditions. The use of modulators of AMPK and optionally a modulator of Galectin 9, TAK1 and/or a lysosomotropic agent for the treatment of autophagy-mediated disease states and/or conditions is described as are pharmaceutical compositions.

公开(公告)号：US20230357309A1

公开(公告)日：2023-11-09

申请号：US18211816

申请日：2023-06-20

Applicant: EMORY UNIVERSITY

Inventor： DAVID BRIAN GUTHRIE ,  MARK ANDREW LOOKWOOD ,  MICHAEL G. NATCHUS ,  DENNIS C. LIOTTA ,  DONALD G. STEIN ,  IQBAL SAYEED

IPC: C07J41/00 ,  C07J51/00 ,  C07J43/00 ,  A61K31/661 ,  A61K31/57 ,  A61K45/06 ,  A61K31/58

CPC classification number: C07J41/0016 ,  C07J41/005 ,  C07J51/00 ,  C07J43/003 ,  A61K31/661 ,  A61K31/57 ,  A61K45/06 ,  A61K31/58 ,  Y02A50/30

Abstract: This disclosure relates to progesterone phosphate derivatives and uses related thereto. In certain embodiments, the disclosure relates to compounds disclosed herein and uses for managing inflammation such as those resulting from traumatic brain injury or stroke.

公开(公告)号：US11806351B2

公开(公告)日：2023-11-07

申请号：US17738027

申请日：2022-05-06

Applicant: TERA STONE Co., Ltd

Inventor： Tomohisa Nagamatsu ,  Norio Akaike

IPC: A61K31/519 ,  A61K31/58 ,  A61P25/28

CPC classification number: A61K31/519 ,  A61K31/58 ,  A61P25/28

Abstract: Problem: to provide an activator for activating intracellular ATP production. Solution: use of deazaflavino-testosterone compound represented by the following formula (III):




wherein, R1 represents a hydrogen atom, an alkyl group, a halogen-substituted alkyl group, a carboxy-substituted alkyl group, a phenyl group, or a phenyl group substituted by one of a halogen atom, a lower alkyl group, or a lower alkoxy group and R2 represents an alkyl group, a cycloalkyl group, a phenyl-substituted lower alkyl group, a phenyl group, a phenyl group substituted by one of a halogen atom, a lower alkyl group, or a lower alkoxy group, or a lower alkyl disubstituted phenyl group for activating intracellular ATP production,



the use comprising introducing said deazaflavino-testosterone compound to a human-derived neuron cells, wherein said deazaflavino-testosterone compound is used as a coenzyme factor effective for activating intracellular ATP production.

公开(公告)号：US11806313B2

公开(公告)日：2023-11-07

申请号：US18064587

申请日：2022-12-12

Applicant: Hunan Huize Biopharma S & T Co., Ltd

Inventor： Mulin Yi

IPC: A61K9/107 ,  A61P15/00 ,  A61P35/00 ,  A61K9/48 ,  A61K31/58 ,  A61K47/14 ,  A61K47/44

CPC classification number: A61K9/1075 ,  A61K9/4858 ,  A61K31/58 ,  A61K47/14 ,  A61K47/44 ,  A61P15/00 ,  A61P35/00

Abstract: Disclosed is a self-microemulsion system for loading abiraterone acetate, and a composition and an application thereof. The self-microemulsion system for loading abiraterone acetate has excellent solubility and stability for abiraterone acetate, and the composition formed by dissolving abiraterone acetate in this system can significantly reduce the effect of food on the absorption of abiraterone acetate, and reduce the differences between preprandial administration and postprandial administration, thus making it possible to take the medicament on both an empty and a full stomach and reducing the limitation for the time of taking medicament.